Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ETIDRONATE VERSUS FLUORIDE FOR TREATMENT OF OSTEOPENIA IN PRIMARY BILIARY-CIRRHOSIS - PRELIMINARY-RESULTS AFTER 2 YEARS
Autore:
GUANABENS N; PARES A; MONEGAL A; PERIS P; PONS F; ALVAREZ L; DEOSABA MJM; ROCA M; TORRA M; RODES J;
Indirizzi:
UNIV BARCELONA,HOSP CLIN & PROV,SERV RHEUMATOL,METAB BONE DIS UNIT,C VILLARROEL 170 BARCELONA 08036 SPAIN UNIV BARCELONA,HOSP CLIN & PROV,LIVER UNIT BARCELONA 08036 SPAIN
Titolo Testata:
Gastroenterology
fascicolo: 1, volume: 113, anno: 1997,
pagine: 219 - 224
SICI:
0016-5085(1997)113:1<219:EVFFTO>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
METABOLIC BONE-DISEASE; POSTMENOPAUSAL OSTEOPOROSIS; 25-HYDROXYVITAMIN-D3 TREATMENT; SODIUM-FLUORIDE; LIVER-DISEASE; FRACTURE RATE; WOMEN; TURNOVER; CALCITONIN; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
27
Recensione:
Indirizzi per estratti:
Citazione:
N. Guanabens et al., "ETIDRONATE VERSUS FLUORIDE FOR TREATMENT OF OSTEOPENIA IN PRIMARY BILIARY-CIRRHOSIS - PRELIMINARY-RESULTS AFTER 2 YEARS", Gastroenterology, 113(1), 1997, pp. 219-224

Abstract

Background & Aims: Because osteopenia increases morbidity of primary biliary cirrhosis (PBC), the effects of cyclical etidronate vs, sodiumfluoride on bone mass were compared in patients with PBC. Methods: Thirty-two women with PBC were randomly assigned to receive etidronate (400 mg/day during 14 days every 3 months) or fluoride (50 mg/day, enteric-coated tablets). Bone mineral density of the lumbar spine and proximal femur were measured initially and every 6 months. Bone fractures were also evaluated. Results: Sixteen patients were allocated into each group, which were comparable with respect to the severity of PBC andosteopenia. Thirteen patients with etidronate and 10 patients with fluoride completed 2 years in the study. In the etidronate group, bone mineral density increased in the lumbar spine (P = 0.02) and did not change in the proximal femur. In the fluoride group, lumbar bone mineraldensity did not change but femoral bone mass decreased, particularly in the Ward's triangle. Two patients in the fluoride and none in the etidronate group developed new vertebral fractures, and the number of new nonvertebral fractures was similar in both groups. Neither treatment impaired liver function or cholestasis. Conclusions: Cyclical etidronate is more effective and better tolerated than sodium fluoride in preventing bone loss in PBC.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/12/20 alle ore 15:28:56